Cerecor Turns The LIGHT Back On As Avalo, With PRV Haul In Sight
Anti-LIGHT Focus On IBD Expanded To COVID-19 ARDS
Executive Summary
The former Cerecor boasts four pipeline assets that could yield US FDA priority review vouchers. Having divested CNS assets, the renamed firm will focus on IBD with first-in-class anti-LIGHT candidate, plus immunology and rare diseases.
You may also be interested in...
Finance Watch: Bausch + Lomb Completes Split From Bausch Health Via IPO
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.
Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Priority Review Voucher Fee Decreases For FY 2021 May Reflect US FDA Personnel Changes
In part because assessment costs plummeted in FY 2019, the FY 2021 fee to redeem a priority review voucher will be 37% less than the previous year.